The use of warfarin significantly reduces the risk of stroke among patients with atrial fibrillation (AF). Unfortunately, up to 60% of patients discontinue therapy within the first year.1 Prior studies did not assess the quality of warfarin therapy or the occurrence of electrical cardioversion (ECV) or radiofrequency ablation (RFA) as predictors of discontinuation of warfarin therapy.
Barnes GD, Kaatz S, Lopez A, Gu X, Kozlowski J, Krol GD, Froehlich JB. Discontinuation of Warfarin Therapy for Patients With Atrial FibrillationThe Michigan Anticoagulation Quality Improvement Initiative Experience. JAMA Cardiol. 2017;2(3):341-343. doi:10.1001/jamacardio.2016.5041